$APYP
APPYEA, INC Stock $apyp

$apyp Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000149315223009907 Filed on March 31, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$430.0K	$430.0K	$2.033M
YoY Change	-5.49%		219.15%
% of Gross Profit
Research & Development	$9.000K	$60.00K	$129.0K
YoY Change	-64.0%		59.26%
% of Gross Profit
Depreciation & Amortization	$6.000K	$0.00	$200.00
YoY Change	0.0%	-100.0%	-99.0%
% of Gross Profit
Operating Expenses	$9.000K	$490.0K	$2.162M
YoY Change	-98.13%		201.11%
Operating Profit	-$436.0K		-$2.162M
YoY Change	-9.17%		201.11%
Interest Expense	-$20.00K	$10.00K	-$50.00K
YoY Change			400.0%
% of Operating Profit
Other Income/Expense, Net	-$19.00K	-$90.00K	-$52.00K
YoY Change	-218.75%		766.67%
Pretax Income	-$290.0K	-$570.0K	-$1.300M
YoY Change			-59.12%
Income Tax
% Of Pretax Income
Net Earnings	-$289.0K	-$570.0K	-$1.304M
YoY Change	-138.43%		-58.98%
Net Earnings / Revenue
Basic Earnings Per Share	$0.00		-$0.01
Diluted Earnings Per Share	$0.00	$0.00	-$0.01
COMMON SHARES
Basic Shares Outstanding	228.8M shares	220.9M shares	219.6M shares
Diluted Shares Outstanding	225.2M shares		219.6M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$100.0K	$60.00K	$60.00K
YoY Change			-71.43%
Cash & Equivalents	$100.0K	$60.00K	$60.00K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables	$20.00K	$20.00K	$20.00K
Other Receivables	$18.00K	$19.00K	$0.00
Total Short-Term Assets	$118.0K	$79.00K	$80.00K
YoY Change		-77.81%	-77.78%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.000K	$2.000K	$0.00
YoY Change		0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$119.0K	$126.0K	$130.0K
YoY Change		-16.0%	-13.33%
TOTAL ASSETS
Total Short-Term Assets	$118.0K	$79.00K	$80.00K
Total Long-Term Assets	$119.0K	$126.0K	$130.0K
Total Assets	$237.0K	$205.0K	$210.0K
YoY Change		-59.49%	-58.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$40.00K	$70.00K	$70.00K
YoY Change			133.33%
Accrued Expenses	$420.0K	$62.00K	$330.0K
YoY Change		376.92%	560.0%
Deferred Revenue
YoY Change
Short-Term Debt	$620.0K	$693.0K	$810.0K
YoY Change		518.75%	252.17%
Long-Term Debt Due	$1.440M	$1.530M	$1.530M
YoY Change			-20.73%
Total Short-Term Liabilities	$2.648M	$2.768M	$2.770M
YoY Change		9.8%	9.92%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00		$0.00
YoY Change			-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.648M	$2.768M	$2.770M
Total Long-Term Liabilities	$0.00		$0.00
Total Liabilities	$2.648M	$2.768M	$2.750M
YoY Change		-5.72%	-5.82%
SHAREHOLDERS EQUITY
Retained Earnings	-$4.798M	-$4.509M
YoY Change		40.69%
Common Stock	$22.00K	$21.00K
YoY Change		0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$2.397M	-$2.549M	-$2.550M
YoY Change
Total Liabilities & Shareholders Equity	$237.0K	$205.0K	$210.0K
YoY Change		-59.49%	-58.82%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$289.0K	-$570.0K	-$1.304M
YoY Change	-138.43%		-58.98%
Depreciation, Depletion And Amortization	$6.000K	$0.00	$200.00
YoY Change	0.0%	-100.0%	-99.0%
Cash From Operating Activities	-$97.00K	-$90.00K	-$595.0K
YoY Change	-23.62%	12.5%	254.17%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Cash From Investing Activities		$0.00
YoY Change		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$141.0K	50.00K	$442.0K
YoY Change		-28.57%	125.51%
NET CHANGE
Cash From Operating Activities	-$97.00K	-90.00K	-$595.0K
Cash From Investing Activities		0.000
Cash From Financing Activities	$141.0K	50.00K	$442.0K
Net Change In Cash	$40.00K	-40.00K	-$146.0K
YoY Change	-131.5%	-125.0%	-174.87%
FREE CASH FLOW
Cash From Operating Activities	-$97.00K	-$90.00K	-$595.0K
Capital Expenditures
Free Cash Flow			-$595.0K
YoY Change			247.95%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001568969
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent		usd
CY2022Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent		usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	APYP	Stock Payables StockPayables		usd
CY2022	us-gaap	Noncash Merger Related Costs NoncashMergerRelatedCosts		usd
CY2021	APYP	Change In Fair Value Of Convertible Loans And Warrant Liability ChangeInFairValueOfConvertibleLoansAndWarrantLiability		usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
CY2022	us-gaap	Noncash Merger Related Costs NoncashMergerRelatedCosts		usd
CY2021	APYP	Change In Fair Value Of Convertible Loans And Warrant Liability ChangeInFairValueOfConvertibleLoansAndWarrantLiability		usd
CY2021	APYP	Financial Expenses Net FinancialExpensesNet		usd
CY2021	APYP	Increase Decrease In Accounts Payable Related Party IncreaseDecreaseInAccountsPayableRelatedParty		usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2022	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition		usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
CY2021	APYP	Proceeds From Repayment On Account Of Convertible Loans Including Interest ProceedsFromRepaymentOnAccountOfConvertibleLoansIncludingInterest		usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations		usd
CY2022	APYP	Working Capital Excluding Cash And Cash Equivalents Net WorkingCapitalExcludingCashAndCashEquivalentsNet		usd
CY2022	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction		usd
CY2022	APYP	Cost Of Reverse Merger CostOfReverseMerger		usd
CY2022	APYP	Shares Issued In Reverse Merger SharesIssuedInReverseMerger		usd
CY2022	APYP	Cash Acquired In Reverse Merger CashAcquiredInReverseMerger		usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure		usd
CY2022Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent		usd
CY2021Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent		usd
CY2022	us-gaap	Management Fee Expense ManagementFeeExpense		usd
CY2022	us-gaap	Interest Income Related Party InterestIncomeRelatedParty		usd
CY2022Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding		usd
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	000-55403
CY2022	dei	Entity Registrant Name EntityRegistrantName	APPYEA, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-1496846
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	16 Natan Alterman St
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Gan Yavne
CY2022	dei	Entity Address Country EntityAddressCountry	IL
CY2022	dei	City Area Code CityAreaCode	(800)
CY2022	dei	Local Phone Number LocalPhoneNumber	674-3561
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	228815414	shares
CY2022Q2	dei	Entity Public Float EntityPublicFloat	3392605.8	usd
CY2022	dei	Auditor Firm AuditorFirmId	540184942
CY2022	dei	Auditor Name AuditorName	BARZILY AND CO., CPA’s
CY2022	dei	Auditor Location AuditorLocation	Jerusalem, Israel
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	60000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	206000	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	19000	usd
CY2021Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	13000	usd
CY2021Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	137000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	79000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	356000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	124000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	148000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	126000	usd
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	150000	usd
CY2022Q4	us-gaap	Assets Assets	205000	usd
CY2021Q4	us-gaap	Assets Assets	506000	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	67000	usd
CY2021Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	30000	usd
CY2022Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	340000	usd
CY2021Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	65000	usd
CY2022Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	80000	usd
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	89000	usd
CY2022Q4	APYP	Convertible Loans Related Party Current ConvertibleLoansRelatedPartyCurrent	36000	usd
CY2021Q4	APYP	Convertible Loans Related Party Current ConvertibleLoansRelatedPartyCurrent	32000	usd
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	693000	usd
CY2021Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	112000	usd
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	1528000	usd
CY2021Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	1933000	usd
CY2022Q4	APYP	Warrants Liability WarrantsLiability	24000	usd
CY2021Q4	APYP	Warrants Liability WarrantsLiability	260000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2768000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2521000	usd
CY2021Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	415000	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	415000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	2768000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	2936000	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	21000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	21000	usd
CY2022Q4	APYP	Stock Payables StockPayables	27000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1912000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	768000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4509000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3205000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2549000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-2416000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-14000	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	-14000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2563000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2430000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	205000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	506000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	129000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	81000	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	16000	usd
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	5000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2017000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	632000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-2162000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-718000	usd
CY2021	us-gaap	Noncash Merger Related Costs NoncashMergerRelatedCosts	2457000	usd
CY2022	APYP	Change In Fair Value Of Convertible Loans And Warrant Liability ChangeInFairValueOfConvertibleLoansAndWarrantLiability	-910000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-52000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-1304000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-3181000	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-2000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-1304000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-3179000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.005
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.026
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	219588562	shares
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-37000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	299000	usd
CY2021	APYP	Stock Issued During Period Value Reverse Stock Splits StockIssuedDuringPeriodValueReverseStockSplits	4000	shares
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	485000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-3181000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2430000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2430000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	102000	usd
CY2022	APYP	Stock Issued During Period Value Stock Payables StockIssuedDuringPeriodValueStockPayables	27000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1042000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-1304000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2563000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2563000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-1304000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-3181000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	24000	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	16000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1144000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	485000	usd
CY2021	us-gaap	Noncash Merger Related Costs NoncashMergerRelatedCosts	2457000	usd
CY2022	APYP	Change In Fair Value Of Convertible Loans And Warrant Liability ChangeInFairValueOfConvertibleLoansAndWarrantLiability	-910000	usd
CY2022	APYP	Financial Expenses Net FinancialExpensesNet	52000	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-143000	usd
CY2021	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-54000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	171000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1000	usd
CY2022	APYP	Increase Decrease In Accounts Payable Related Party IncreaseDecreaseInAccountsPayableRelatedParty	85000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-595000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-168000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3000	usd
CY2021	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	170000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	167000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	136000	usd
CY2022	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	14000	usd
CY2021	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	60000	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	458000	usd
CY2022	APYP	Proceeds From Repayment On Account Of Convertible Loans Including Interest ProceedsFromRepaymentOnAccountOfConvertibleLoansIncludingInterest	-30000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	442000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	196000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-146000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	195000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	206000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	11000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	60000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	206000	usd
CY2021	us-gaap	Stock Issued1 StockIssued1	163000	usd
CY2021	APYP	Working Capital Excluding Cash And Cash Equivalents Net WorkingCapitalExcludingCashAndCashEquivalentsNet	-129000	usd
CY2021	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	2752000	usd
CY2021	APYP	Cost Of Reverse Merger CostOfReverseMerger	-2457000	usd
CY2021	APYP	Shares Issued In Reverse Merger SharesIssuedInReverseMerger	4000	usd
CY2021	APYP	Cash Acquired In Reverse Merger CashAcquiredInReverseMerger	170000	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_806_eus-gaap--NatureOfOperations_zAeK6ow6Vbt4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1</b></span> - <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_820_zgFS8TsPCYEc">GENERAL</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.8in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AppYea, Inc. (“AppYea”, “the Company”, “we” or “us”) was incorporated in the State of South Dakota on November 26, 2012 to engage in the acquisition, purchase, maintenance and creation of mobile software applications. The Company is in the development stage with no significant revenues and no operating history. On November 1, 2021 the Company was redomiciled in the State of Nevada.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.8in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s common stock is traded on the OTC Markets, OTCQB tier, under the symbol “APYP”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reverse merger</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 56.7pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.8in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In anticipation of the reverse merger described below, on July 2, 2021, Boris Molchadsky a majority shareholder of the Company, acquired in a private transaction from the former majority shareholder consisting of two hundred and twenty-five thousand (<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20210702__20210702__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BorisMolchadskyMember_zHUxAFFfsTj3" title="Number of shares acquired">225,000</span>) Shares of Series A Preferred Stock of the Company. <span id="xdx_905_eus-gaap--PreferredStockVotingRights_c20210702__20210702__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BorisMolchadskyMember_zRj4Jsynzo64" title="Preferred stock voting rights">The Series A Preferred Shares have the right to vote 1,000 to 1 as shares of common stock and are convertible into 1,500 to 1 of the shares of common stock of the Company.</span> The acquisition of the Preferred Shares provided Boris Molchadsky with control of a majority of the Company’s voting equity capital.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 63.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.8in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 2, 2021, the Company entered into a stock exchange agreement with SleepX Ltd., a company formed under the laws of the State of Israel (“SleepX”) and controlled by the majority shareholder of AppYea, Pursuant to the agreement, the outstanding equity capital consisting of <span id="xdx_90C_eus-gaap--SharesOutstanding_iI_pid_c20210802__us-gaap--TypeOfArrangementAxis__custom--StockExchangeAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--SleepXLtdMember_z1O0gzRAYcxf" title="Outstanding equity capital">1,724</span> common shares of SleepX was exchanged for <span id="xdx_904_eus-gaap--ConversionOfStockSharesConverted1_c20210801__20210802__us-gaap--TypeOfArrangementAxis__custom--StockExchangeAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--SleepXLtdMember_z9FtxvBZdwMf" title="Number shares exchanged for common stock">174,595,634</span> shares of common stock of the Company, based on the agreement that determined that to SleepX shareholders will be issued common shares in the amount that will result in them holding <span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20210802__us-gaap--TypeOfArrangementAxis__custom--StockExchangeAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SleepXLtdMember_zkjHiTaCeoof" title="Equity ownership percentage">80</span>% of the issued common shares of AppYea. As a result, SleepX became a wholly owned subsidiary of the Company. On December 31, 2021, the terms of the agreement were fulfilled; however, the issuance of the shares to SleepX shareholders, due to administrative matters, was completed in March 2022 after the Company completed a reverse stock split (see Note 9E).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.8in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of the transaction mentioned above, as of December 31, 2022, Mr. Molchadsky controls approximately <span id="xdx_90A_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BorisMolchadskyMember__us-gaap--BusinessAcquisitionAxis__custom--SleepXLtdMember_zr6SlmMbFfrb" title="Voting interest rate">71.4</span>% of the total voting power of AppYea.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.8in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SleepX is an Israeli research and development company that has developed a unique product for monitoring and treating sleep apnea and snoring. The technology is protected by several international patents and, subject to raising working capital, of which no assurance can be provided, the Company plans to start serial production in 2023. The Company will focus on further development and commercialization of the products. Its strategy will include continued investment in research and development and new initiatives in sales and marketing.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.8in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SleepX has incorporated, together with an unrelated third party, a privately held company under the laws of the State of Israel named Ta-nooma Ltd. (“Ta-nooma”). Ta-nooma has developed sleeping monitoring technology for which patent applications were filed and has no revenue from operations. Since its incorporation and as of the financial statements date, Sleepx holds <span id="xdx_904_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20221231__us-gaap--BusinessAcquisitionAxis__custom--SleepXLtdMember_zlVBvqIA0Cxh" title="Voting interest rate">66.7</span>% of the voting interest of Ta-nooma.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.8in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition to SleepX, the Company has four wholly owned subsidiaries with no active operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>APPYEA INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"/> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO THE FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"/> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 0.65in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1</b></span> </td> <td style="width: 0.1in">-</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GENERAL (cont.)</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 63.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.8in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accounting treatment of Acquisition</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 63.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.8in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AppYea did not have material operations as of the date of the transactions and the Acquisition was accounted for as a reverse merger -a reverse capitalization. The entity that issues securities (the legal acquirer or-AppYea) is identified as the acquiree for accounting purposes. The entity whose interests are acquired (SleepX.) is the acquirer for accounting purposes. Since SleepX is considered the accounting acquirer, these consolidated financial statements are prepared as a continuation of the operations of SleepX, except for the legal capital which is of AppYea.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 63.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.8in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The legal capital of AppYea in the financial statements is restated using the exchange ratio established in the stock exchange agreement to reflect the number of shares of the legal acquirer issued in the reverse merger.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 63.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 63.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.8in; text-align: justify">Following the above, as of December 31, 2021, the date of the transaction, the fair value of the net liabilities of AppYea was in the amount of $<span id="xdx_905_eus-gaap--LiabilitiesFairValueAdjustment_c20210101__20211231_zgcYM5EwtC16">2,453,000</span>.</p> <p style="font: 11pt/110% Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.8in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This amount is presented at cost of the reverse merger in the statement of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 63.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.8in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial position</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 63.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.8in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The financial statements are presented on a going concern basis. The Company has not yet generated any material revenues, has suffered recurring losses from operations and is dependent upon external sources for financing its operations. As of December 31, 2022, the Company has an accumulated deficit of <span id="xdx_90A_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20221231_zXJsM4HEU78f">4,509,000</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and a stockholders’ deficiency of <span id="xdx_904_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iNI_di_c20221231_zzXx5KKwD46b">2,563,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. These matters, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The Company intends to continue to finance its operating activities by raising capital. There are no assurances that the Company will be successful in obtaining an adequate level of financing needed for its long-term research and development activities on commercially reasonable terms or at all. If the Company will not have sufficient liquidity resources, the Company may not be able to continue the development of its product candidates or may be required to implement cost reduction measures and may be required to delay part of its development programs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 63.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.8in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The financial statements do not include any adjustments for the values of assets and liabilities and their classification that may be necessary in the event that the Company is no longer able to continue its operations as a “going concern”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 63.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 63.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 63.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>APPYEA INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"/> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO THE FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2021	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	2453000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4509000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2563000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_844_eus-gaap--UseOfEstimates_zP658uNWy7n8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 56.9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.4in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86D_znemQrqh8wXk">Use of estimates</span>:</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 85.05pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.15in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying Consolidated Financial Statements are prepared in accordance with accounting principles generally accepted in the United States of America which require management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses. Significant estimates include the ability to continue as a going concern, the recoverability of long-lived assets, the recoverability of amounts due from related parties, the valuation of stock-based compensation and certain debt and derivative liabilities, recognition of loss contingencies and deferred tax valuation allowances. Actual results could differ from those estimates. Changes in facts and circumstances may result in revised estimates, which would be recorded in the period in which they become known. See note 8 regarding the Convertible Loans and Warrants estimations.</span></p>
CY2022Q4	us-gaap	Foreign Currency Exchange Rate Translation1 ForeignCurrencyExchangeRateTranslation1	3.519	pure
CY2021Q4	us-gaap	Foreign Currency Exchange Rate Translation1 ForeignCurrencyExchangeRateTranslation1	3.110	pure
CY2022	APYP	Severance Rate Of Employees Monthly Salary SeveranceRateOfEmployeesMonthlySalary	0.0833	pure
CY2022	us-gaap	Derivatives Reporting Of Derivative Activity DerivativesReportingOfDerivativeActivity	<p id="xdx_84A_eus-gaap--DerivativesReportingOfDerivativeActivity_zUC6PG2VgGFd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="text-align: justify; width: 0.4in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td> <td style="text-align: justify"><span id="xdx_86D_zXhkbXxS0Yfk">Derivative Financial Instruments</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 56.7pt; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.15in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. For option-based simple derivative financial instruments, the Company uses an option-pricing model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. We do not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks.</span></p>
CY2022Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	2257000	usd
CY2022Q4	APYP	Warrants Fair Value Disclosure WarrantsFairValueDisclosure	24000	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_z6pYQoVt0g62" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 85.05pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.4in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_862_zAimA3YBOoj5">Concentrations of credit risks</span>:</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 85.05pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.15in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The financial instruments include cash, accounts receivable, accounts payable, accrued expenses, loans payable, due to officers and derivative financial instruments. Balances in various cash accounts may at times exceed federally insured limits. We have not experienced any losses in such accounts. Cash and cash equivalents are invested in major banks in Israel and United States. Generally, these deposits may be redeemed upon demand and therefore, management believes there is minimal risk. Other than certain warrant and convertible instruments (derivative financial instruments)., we believe the carrying values of our financial instruments approximate their fair values because they are short term in nature or payable on demand. Our derivative financial instruments are carried at a measured fair value. The Company has no significant off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</span></p>
CY2021Q4	us-gaap	Other Receivables OtherReceivables	6000	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	19000	usd
CY2021Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	13000	usd
CY2022Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	49824701	shares
CY2021Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	1586926	shares
CY2022Q4	us-gaap	Other Assets OtherAssets	12000	usd
CY2021Q4	us-gaap	Other Assets OtherAssets	7000	usd
CY2022Q4	us-gaap	Other Receivables OtherReceivables	7000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2000	usd
CY2022	us-gaap	Depreciation Depreciation	200	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	163000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	39000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	124000	usd
CY2022	us-gaap	Adjustment For Amortization AdjustmentForAmortization	23285	usd
CY2021	us-gaap	Adjustment For Amortization AdjustmentForAmortization	15000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	62000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13000	usd
CY2022Q4	us-gaap	Deferred Income Current DeferredIncomeCurrent	6000	usd
CY2021Q4	us-gaap	Deferred Income Current DeferredIncomeCurrent	5000	usd
CY2022Q4	APYP	Government Institutions GovernmentInstitutions	4000	usd
CY2021Q4	APYP	Government Institutions GovernmentInstitutions	15000	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	268000	usd
CY2021Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	32000	usd
CY2022Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	340000	usd
CY2021Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	65000	usd
CY2021Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	137000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	268000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	46000	usd
CY2022Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	140000	usd
CY2022Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	80000	usd
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	89000	usd
CY2022Q4	APYP	Convertible Loans Related Party Current ConvertibleLoansRelatedPartyCurrent	36000	usd
CY2021Q4	APYP	Convertible Loans Related Party Current ConvertibleLoansRelatedPartyCurrent	32000	usd
CY2022	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	1356000	usd
CY2021	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	595000	usd
CY2021	us-gaap	Management Fee Expense ManagementFeeExpense	60000	usd
CY2021	us-gaap	Interest Income Related Party InterestIncomeRelatedParty	2000	usd
CY2021Q4	us-gaap	Convertible Debt ConvertibleDebt	2492000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	526000	usd
CY2022	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable	743000	usd
CY2022Q4	us-gaap	Convertible Debt ConvertibleDebt	2257000	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	693410	usd
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	111828	usd
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	220930798	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	220930798	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	218246326	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	218246326	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	10000000000	shares
CY2022	us-gaap	Salaries And Wages SalariesAndWages	1356000	usd
CY2021	us-gaap	Salaries And Wages SalariesAndWages	528000	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	605000	usd
CY2021	us-gaap	Professional Fees ProfessionalFees	67000	usd
CY2022	APYP	Vehicle Expenses VehicleExpenses	10000	usd
CY2021	APYP	Vehicle Expenses VehicleExpenses	7000	usd
CY2022	us-gaap	Business Development BusinessDevelopment	1000	usd
CY2021	us-gaap	Business Development BusinessDevelopment	5000	usd
CY2022	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	45000	usd
CY2021	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	25000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2017000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	632000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost	1049379000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost	485096000	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	74850	usd
CY2022Q4	us-gaap	Defined Benefit Plan Funded Percentage DefinedBenefitPlanFundedPercentage	0.0833	pure
CY2021Q3	us-gaap	Officers Compensation OfficersCompensation	20000
CY2021Q3	us-gaap	Officers Compensation OfficersCompensation	5683	usd
CY2022Q4	APYP	Officers Compensation Shares OfficersCompensationShares	9205450	shares
CY2021Q4	APYP	Officers Compensation Shares OfficersCompensationShares	9093597	shares
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P2Y
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	1.877	pure
CY2021Q3	APYP	Common Stock Par Or Stated Market Value CommonStockParOrStatedMarketValue	0.76
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.003	pure
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	6904087	shares
CY2022	APYP	Stock Issued During Period Shares Stock Options Unexercised StockIssuedDuringPeriodSharesStockOptionsUnexercised	2301363	shares
CY2022	APYP	Share Based Compensation Arrangement By Share Based Payment Award Options Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice	0.0001
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Expiration Date ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate	2031-07-01
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1049379	usd
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	485096	usd
CY2022	us-gaap	Credit Derivative Liquidation Proceeds Percentage CreditDerivativeLiquidationProceedsPercentage	0.015	pure
CY2022Q4	APYP	Bonus Bonus	10000000	usd
CY2022Q4	APYP	Revenue Capital Percentage RevenueCapitalPercentage	0.010	pure
CY2022Q4	APYP	Accumulated Revenues AccumulatedRevenues	20000000	usd
CY2022	us-gaap	Officers Compensation OfficersCompensation	20000
CY2022	us-gaap	Officers Compensation OfficersCompensation	5683	usd
CY2022Q4	APYP	Additional Revenues AdditionalRevenues	10000
CY2022Q4	APYP	Additional Revenues AdditionalRevenues	2842	usd
CY2022Q4	APYP	Accumulated Revenue AccumulatedRevenue	1000000	usd
CY2022Q4	APYP	Management Fees ManagementFees	72000
CY2022Q4	APYP	Management Fees ManagementFees	20460	usd
CY2022	APYP	Management Fees Percentage ManagementFeesPercentage	0.50	pure
CY2022Q4	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	40000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	178000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	64000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	178000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	64000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	178000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	64000	usd

Files In Submission

Name	View Source	Status
form10-k_htm.xml	Edgar Link	completed
0001493152-23-009907-index-headers.html	Edgar Link	pending
0001493152-23-009907-index.html	Edgar Link	pending
0001493152-23-009907.txt	Edgar Link	pending
0001493152-23-009907-xbrl.zip	Edgar Link	pending
apyp-20221231.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_001.jpg	Edgar Link	pending
apyp-20221231_cal.xml	Edgar Link	unprocessable
apyp-20221231_def.xml	Edgar Link	unprocessable
apyp-20221231_pre.xml	Edgar Link	unprocessable
apyp-20221231_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$APYP
APPYEA, INC Stock $apyp

2023 Q1 Form 10-K Financial Statement

#000149315223009907 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APYP APPYEA, INC Stock $apyp

2023 Q1 Form 10-K Financial Statement

#000149315223009907 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APYP
APPYEA, INC Stock $apyp